Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk (TIERRA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00874185
First received: April 1, 2009
Last updated: February 12, 2013
Last verified: February 2013

April 1, 2009
February 12, 2013
December 2007
May 2008   (final data collection date for primary outcome measure)
  • EDITS [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • SEAR [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00874185 on ClinicalTrials.gov Archive Site
Medication prescribed [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk
Satisfaction With Treatment In Patients With Erectile Dysfunction And Cardiovascular Risk And/Or Previous Cardiovascular Event.

Evaluate satisfaction in people treated with IPDE5 inhibitors over time

12 first patients that are eligible

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

People with cv risk

Erectile Dysfunction
Not Provided
Questionnaire
filling in questionnaires
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
720
May 2008
May 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • CV risk factors
  • Male above 18

Exclusion Criteria:

  • Non-informed consent
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00874185
A1481256, A1481256
No
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP